EquityZen Growth Technology Fund LLC - Series 2154
Raised
$1M
Investors
61
Min Invest
$5,014
AltStreet Analysis
·Generated from EDGAR primary sources
EquityZen Growth Technology Fund LLC - Series 2154 is a Delaware limited liability company filed by EquityZen Advisors LLC and Phil Haslett that raised $1.5M from 61 investors under Rule 506(b) and Section 3(c)(1). The offering has a $5K minimum investment and is part of EquityZen's pre-IPO secondary market platform, which has filed over 1,800 related entities.
This pre-IPO pooled investment fund uses the standard 506(b)/3(c)(1) exemption structure common to EquityZen's series vehicles. The $5K minimum investment is typical for retail-accessible secondary market platforms, enabling broad participation in late-stage private company equity that would otherwise require institutional minimums.
Data Flags
EDGAR Filing Data
Form D — Primary Source
View on SEC.govRelated Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
EquityZen Advisors LLC
Executive Officer, Director · New York, NY
Phil Haslett
Executive Officer, Director · New York, NY
Is this your offering?
Claim this profile to add contact information, team members, LinkedIn profiles, fund history, and additional financial data. EDGAR-sourced data and AltStreet analysis cannot be edited, but corrections can be requested for verifiable inaccuracies.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.
